Full Press Release Details
CureVac Announces Closing of $250 million
Follow-on Public Offering of Common Shares
Germany/ BOSTON, USA - February 10, 2023 - CureVac N.V. (Nasdaq: CVAC) ("CureVac"), a global biopharmaceutical
company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), announced today
the closing of its follow-on public offering of 27,027,028 common shares, at a public offering price of $9.25 per common share, for total
gross proceeds of approximately $250 million before deducting underwriting discounts and commissions and offering expenses payable by
Sachs & Co. LLC, Jefferies LLC, and SVB Securities LLC acted as bookrunners for the offering. Van Lanschot Kempen (USA) Inc.
acted as lead manager for the offering.
was made pursuant to an effective shelf registration statement on Form F-3 filed with the U.S. Securities and Exchange Commission ("SEC")
on September 17, 2021. A final prospectus supplement and accompanying prospectus relating to and describing the final terms of the offering
has been filed with the SEC and is available from the SEC's website located at www.sec.gov or from Goldman Sachs & Co. LLC,
Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by
emailing prospectus-ny@ny.email.gs.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York,
New York 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; and SVB Securities LLC, Attention:
Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@svbsecurities.com.
release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities
in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction.
(Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of
expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes. The principle of
CureVac's proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own
proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered in a collaboration with GSK to jointly develop
new products in prophylactic vaccines for infectious diseases based on CureVac's second-generation mRNA technology. This
collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine
technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic
vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac N.V. has its headquarters in
T bingen, Germany, and has more than 1,000 employees across its sites in Germany, the Netherlands, Belgium, Switzerland and the
CureVac Investor Relations Contact
Fakih, Vice President Corporate Communications and Investor Relations
CureVac Media Contact
Bettina J dicke-Braas, Manager Communications
CureVac, T bingen, Germany
T: +49 7071 9883-1087
Forward-Looking Statements CureVac
This press release contains statements that constitute
"forward looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995,
including statements that express the opinions, expectations, beliefs, plans, objectives, assumptions or projections of CureVac N.V.
and/or its wholly owned subsidiaries CureVac SE, CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac Corporate Services
GmbH, CureVac RNA Printer GmbH, CureVac Belgium SA and CureVac Netherlands B.V. (the "company") regarding future events or
future results, in contrast with statements that reflect historical facts. In some cases, you can identify such forward-looking statements
by terminology such as "anticipate," "intend," "believe," "estimate," "plan,"
"seek," "project," or "expect," "may," "will," "would," "could,"
"potential," "intend," or "should," the negative of these terms or similar expressions. Forward-looking
statements are based on management's current beliefs and assumptions and on information currently available to the company. However,
these forward-looking statements are not a guarantee of the company's performance, and you should not place undue reliance on such
statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, including negative
worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, ability to obtain funding, ability
to conduct current and future preclinical studies and clinical trials, the timing, expense and uncertainty of regulatory approval, reliance
on third parties and collaboration partners, ability to commercialize products, ability to manufacture any products, possible changes
in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in
the company's industry, the effects of the COVID-19 pandemic on the company's business and results of operations, ability
to manage growth, reliance on key personnel, reliance on intellectual property protection, ability to provide for patient safety, and
fluctuations of operating results due to the effect of exchange rates or other factors. Such risks and uncertainties may cause the statements
to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the company's
control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included
in this press release are made only as of the date hereof. The company does not undertake, and specifically declines, any obligation
to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or
developments, except as required by law.
For further information, please reference the
company's reports and documents filed with the U.S. Securities and Exchange Commission (SEC). You may get these documents by visiting
EDGAR on the SEC website at www.sec.gov.